-
1
-
-
67449128733
-
The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis. Part II. Validation and final selection
-
Rudwaleit M, van der Heijde D, Landewe R, Listing J, Akkoc N, Brandt J, et al. The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis. Part II. Validation and final selection. Ann Rheum Dis 2009; 68: 777-83.
-
(2009)
Ann Rheum Dis
, vol.68
, pp. 777-783
-
-
Rudwaleit, M.1
Van Der Heijde, D.2
Landewe, R.3
Listing, J.4
Akkoc, N.5
Brandt, J.6
-
2
-
-
0021272107
-
Evaluation of diagnostic criteria for ankylosing spondylitis: A proposal for modification of the New York criteria
-
Van der Linden S, Valkenburg HA, Cats A,. Evaluation of diagnostic criteria for ankylosing spondylitis: a proposal for modification of the New York criteria. Arthritis Rheum 1984; 27: 361-8.
-
(1984)
Arthritis Rheum
, vol.27
, pp. 361-368
-
-
Van Der Linden, S.1
Valkenburg, H.A.2
Cats, A.3
-
3
-
-
79955844276
-
2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis
-
Van der Heijde D, Sieper J, Maksymowych WP, Dougados M, Burgos-Vargas R, Landewe R, et al. 2010 update of the international ASAS recommendations for the use of anti-TNF agents in patients with axial spondyloarthritis. Ann Rheum Dis 2011; 70: 905-8.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 905-908
-
-
Van Der Heijde, D.1
Sieper, J.2
Maksymowych, W.P.3
Dougados, M.4
Burgos-Vargas, R.5
Landewe, R.6
-
4
-
-
47249115716
-
Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: Results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two
-
Haibel H, Rudwaleit M, Listing J, Heldmann F, Wong RL, Kupper H, et al. Efficacy of adalimumab in the treatment of axial spondylarthritis without radiographically defined sacroiliitis: results of a twelve-week randomized, double-blind, placebo-controlled trial followed by an open-label extension up to week fifty-two. Arthritis Rheum 2008; 58: 1981-91.
-
(2008)
Arthritis Rheum
, vol.58
, pp. 1981-1991
-
-
Haibel, H.1
Rudwaleit, M.2
Listing, J.3
Heldmann, F.4
Wong, R.L.5
Kupper, H.6
-
5
-
-
33745894976
-
Efficacy and safety of adalimumab in patients with ankylosing spondylitis: Results of a multicenter, randomized, double-blind, placebo-controlled trial
-
Van der Heijde D, Kivitz A, Schiff MH, Sieper J, Dijkmans BA, Braun J, et al. Efficacy and safety of adalimumab in patients with ankylosing spondylitis: results of a multicenter, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2006; 54: 2136-46.
-
(2006)
Arthritis Rheum
, vol.54
, pp. 2136-2146
-
-
Van Der Heijde, D.1
Kivitz, A.2
Schiff, M.H.3
Sieper, J.4
Dijkmans, B.A.5
Braun, J.6
-
6
-
-
65249142737
-
Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis
-
Barkham N, Keen HI, Coates LC, O'Connor P, Hensor E, Fraser AD, et al. Clinical and imaging efficacy of infliximab in HLA-B27-positive patients with magnetic resonance imaging-determined early sacroiliitis. Arthritis Rheum 2009; 60: 946-54.
-
(2009)
Arthritis Rheum
, vol.60
, pp. 946-954
-
-
Barkham, N.1
Keen, H.I.2
Coates, L.C.3
O'Connor, P.4
Hensor, E.5
Fraser, A.D.6
-
7
-
-
79952330548
-
Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): A 48-week randomised controlled trial
-
Song IH, Hermann K, Haibel H, Althoff CE, Listing J, Burmester G, et al. Effects of etanercept versus sulfasalazine in early axial spondyloarthritis on active inflammatory lesions as detected by whole-body MRI (ESTHER): a 48-week randomised controlled trial. Ann Rheum Dis 2011; 70: 590-6.
-
(2011)
Ann Rheum Dis
, vol.70
, pp. 590-596
-
-
Song, I.H.1
Hermann, K.2
Haibel, H.3
Althoff, C.E.4
Listing, J.5
Burmester, G.6
-
8
-
-
84877606429
-
Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: Results of a randomised placebo controlled strial (ABILITY-1)
-
Sieper J, van der Heijde D, Dougados M, Mease P, Maksymowych WP, Brown MA, et al. Efficacy and safety of adalimumab in patients with non-radiographic axial spondyloarthritis: results of a randomised placebo controlled strial (ABILITY-1). Ann Rheum Dis 2013; 72: 815-22.
-
(2013)
Ann Rheum Dis
, vol.72
, pp. 815-822
-
-
Sieper, J.1
Van Der Heijde, D.2
Dougados, M.3
Mease, P.4
Maksymowych, W.P.5
Brown, M.A.6
-
9
-
-
67649831600
-
The Assessment of SpondyloArthritis international Society (ASAS) handbook: A guide to assess spondyloarthritis
-
Sieper J, Rudwaleit M, Baraliakos X, Brandt J, Braun J, Burgos-Vargas R, et al. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 2009; 68 Suppl 2: ii1-44.
-
(2009)
Ann Rheum Dis
, vol.68
, Issue.SUPPL. 2
-
-
Sieper, J.1
Rudwaleit, M.2
Baraliakos, X.3
Brandt, J.4
Braun, J.5
Burgos-Vargas, R.6
-
10
-
-
0028575453
-
A new approach to defining disease status in ankylosing spondylitis: The Bath Ankylosing Spondylitis Disease Activity Index
-
Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A,. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994; 21: 2286-91.
-
(1994)
J Rheumatol
, vol.21
, pp. 2286-2291
-
-
Garrett, S.1
Jenkinson, T.2
Kennedy, L.G.3
Whitelock, H.4
Gaisford, P.5
Calin, A.6
-
11
-
-
84862553196
-
Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial
-
Song IH, Althoff CE, Haibel H, Hermann KG, Poddubnyy D, Listing J, et al. Frequency and duration of drug-free remission after 1 year of treatment with etanercept versus sulfasalazine in early axial spondyloarthritis: 2 year data of the ESTHER trial. Ann Rheum Dis 2012; 71: 1212-5.
-
(2012)
Ann Rheum Dis
, vol.71
, pp. 1212-1215
-
-
Song, I.H.1
Althoff, C.E.2
Haibel, H.3
Hermann, K.G.4
Poddubnyy, D.5
Listing, J.6
-
12
-
-
77953476984
-
Clinical response and time to active disease following infliximab therapy in patients with HLA-B27 positive very early ankylosing spondylitis
-
Barkham N, Keen HI, Coates LC, O'Connor P, Hensor EM, Fraser A, et al. Clinical response and time to active disease following infliximab therapy in patients with HLA-B27 positive very early ankylosing spondylitis. Ann Rheum Dis 2009; 68 Suppl 3: 72.
-
(2009)
Ann Rheum Dis
, vol.68
, Issue.SUPPL. 3
, pp. 72
-
-
Barkham, N.1
Keen, H.I.2
Coates, L.C.3
O'Connor, P.4
Hensor, E.M.5
Fraser, A.6
|